Precision Medicine

New Science and Precision Medicine are closely linked. New Science is a dynamic combination of the best in science and health technology that is projected to drive 61 percent of biopharma revenues until 2026, representing 81% of anticipated industry revenue growth. Precision Medicine has grown with the mapping of the genome to drive the development of personalized treatments for individuals or patient populations. Both work in combination with new, analytical scientific and technological advances to positively impact the biopharma business and help deliver better health outcomes. Discoveries are being made and tested in the cloud. Artificial intelligence and machine learning algorithms are digesting data lakes and helping drive new discoveries, speed development and provide smarter care. Accelerated development in cell and gene therapies (CGT) is causing a fundamental shift in the traditional biopharmaceutical business model. Both represent a medical revolution.

New Science is driving exceptional growth across multiple therapeutic areas, but primarily in oncology. The one-size-fits-all cancer treatment approach has been replaced by personalized precision medicine. Standard cancer therapies are ineffective in over 75% of patients. One of the highest therapy failure rates for all diseases. Precision oncology is designed to change that.

One of the most exciting areas of innovation in medicine today is in the Cell and Gene Therapy (CGT) sector, with many therapies already changing the industry and patients’ lives. CGT is increasingly being viewed as a superior therapy for life-threatening illnesses such as cancer—and in a growing number of indications, it is being used as a first-line therapeutic approach with the potential to cure diseases entirely. While the science that supports CGT is complex, in the simplest of terms, CGT treats the underlying causes of disease by modifying an individual’s cells and/or genes, typically externally, and re-introducing them to the patient to treat the disease.

As demand for cell and gene therapies increases so does the demand for clinical trials. Industry leaders are focused on technology innovations, but struggle to find a holistic solution. While off-the-shelf digital solutions exist, they are typically focused on fragments of the overall process. As a result, they resort to the creation of bespoke solutions that create redundancies in the system. INTIENT Unify Cell & Gene connects stakeholders across the value chain, enabling manufacturers, supply chain partners and Healthcare Providers (HCPs) to work in a harmonized, standardized way.